Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not an unexpected defense since, as I under it, spoofing isn't strictly illegal on the stock exchange as opposed to the commodities exchange where it is. So nwbo will have to prove harm from the practice. Note: I'm not a lawyer and I didn't even stay at a holiday Inn express so I would welcome corrections to my non lawyerly suppositions.
It only became obvious to us after the lawsuit was filed. It's been obvious to nwbo for a long time as they've been monitoring it for a very long time. Big difference.
They've consistently over optimistic but, no, they're not making up bs narratives
So you invent a new narrative out of thin air with no proof other than you suppose it must be so.
GME was listed on either the nasdaq or the nyse
What proof do you have that oncologists aren't investing in nwbo? It's your supposition so obviously you must have some evidence.
Nwbo was actually mentioned several times
The alternative is standing by and watching the hedge funds bankrupt the company. What alternative do you propose and did you watch the video?
The video is a must watch. What Wes says is at once discouraging/depressing and hopeful. It seems the efforts of the lawyers bringing the nwbo case will determine the future of the company and not the science. Here's hoping they prevail and help expose the massive fraud going on. He gave a timeline of one month before there would be news forthcoming that will expose the fraud so I'm looking forward to that. He also mentioned shareholder actions that would be useful in helping slow the fraud and expose it and those are removing your shares from margin accounts and contacting your representatives in congress and making noise about the issue. Reaffirming LP's call to action from shareholders.
Nasdaq requires a 4 dollar minimum bid price for listing.
It's possible the story gets picked up and run in a major media market. Say, Boston, NYC, Philly.
The pr is for investors, not stockholders.
It is nwbo. Watch the entire report. It says dcvax-l in one of the bullets
It's considered a "hidden ivy" and as such, appropriate for my poor attempt at humor.
Is the ivory league school Colgate-Palmolive?
Wes Christian provides background on stock manipulation and his insights into the way it's done.
https://www.thekomisarscoop.com/2021/07/wes-christian-tells-how-he-uses-law-to-fight-naked-short-sellers/
Number 1 is a non starter for a company trying to generate revenue and grow into profit. Buybacks are for cash rich mature companies and buybacks usually happen to benefit mgt anyway.
Link please
Oct 2015
$NWBO Rolling Stone explains the reasons behind the FUD and the fight to suppress information about the P3 trial and harassment of investigators. Naked short selling will eventually kill our economy unless it is properly enforced. @SECEnfDirector https://t.co/DIIzPRVm4q
— Justin Keister MS DABR (@justinkeister5) December 23, 2022
That's not the only reason to try and bankrupt the company. Shorts would be off the hook and if all the naked shorts speculated are real they would be off the hook for those as well.
You forgot the last 4 letters of that word, bull----
$NWBO clarified (MHRA) that the renewal was needed to keep treating patients until a commercial authorization is signed off on. It appears they did both inspections at the same time. Full auth has a bit more paperwork. Likely soon; won’t give one and snub the other
— Gregory Zivic, MD (@metacollectiveG) December 20, 2022
If I read this right what we're looking at is a renewal, nothing more
Just spoke with company. 2 people from MHRA spent a week doing a deep dive at Sawston inspecting for both renewal and commercialization. The approval process for the latter is more complex but renewal bodes well for manufacturing approval $NWBO $DCVax
— Richard Fairgrieve (@RichFairgrieve) December 20, 2022
Thanks. Appreciate the answer.
Patent applications have to be made in every country individually. Is there evidence of filings for this particular patent in other countries or should we assume nwbo filed simultaneously in other countries.
So then the question, why in Mexico
I can't answer your question but I have one of my own. Why is the patent application in Spanish?
$NWBO Patent issuance fee paid on December 15, 2022 for MX/a/2016/005925 🇲🇽 - Combinations of checkpoint inhibitors and therapeutics to treat cancer
— Henry (@HenryMuney) December 17, 2022
Next, patent issuance. #DCVax-Lhttps://t.co/fyNBPr6PSj pic.twitter.com/9Mf9q4m5AH
Because it's a repeat of at least a dozen posts here saying the same thing? Just guessing.
It's a Friday fire(man) sale.
I take it you don't believe the fda serves the interests of big pharma?
There's news? Do you have a link?
I have concluded this change in the approval process is designed to benefit Merck and other BP. Especially Merck though since we see their early trial results and these changes emerging virtually simultaneously.
The difference between the covid vaccine and a vaccine for gbm is the fatality rate. The covid fatality rate varies widely across age groups and varied with an individual's comorbitities and is miniscule in certain populations, children being the prime example.
GBM is a vastly different disease. Give people credit for being able to make a logical choice based on their individual circumstances.
From a post here a few weeks ago the data in the filing didn't extend beyond March of this year. If that's true then the data from May 10th has not been revealed.
The difference between the Optune Control and Optune Treatment cohorts is alarming. Not sure if a statistician can control for that 40% difference in an analysis but any benefit from the Optune treated group is overstated vs their control by design.
— Lewis Tierney (@Lewis_Tierney) December 12, 2022
IDH mutations are significant prognostic factors for glioblastoma - Since these patients live significantly longer, adjudication is important as treatment effects can be artificially inflated.
— Carlo Rago, PhD (@rago_carlo) December 12, 2022
IDH mut rates in $NVCR vs $NWBO trials
Optune 7%
Optune Cont 5%
DCVax 3%
DCVax Cont 3% pic.twitter.com/DmOUQvE1Xh
I will share a golden nugget later tonight. #Optune vs #Murcidencel$NWBO
— Carlo Rago, PhD (@rago_carlo) December 11, 2022
Thanks Magrit. I watched the entire video and it's engrossing. It's very informative and very depressing at the same time.